
The pharmaceutical company reported 33% revenue growth and a 126% rise in quarterly profit, with CDMO sales up 86%.
Laurus Labs reported a 126% year-on-year rise in Q2FY27 net profit to ₹441 crore, as revenue grew 33% to ₹2,206 crore. Its shares rose following the results.
The Economic Times reported EBITDA of ₹762 crore, up 78%, and an EBITDA margin of 34.5%. As of 06:48 UTC on Friday, the shares traded at ₹2,365, up 5.39% from the previous close.
Contract development and manufacturing organization (CDMO) revenue climbed 86% to ₹875 crore, according to Business Standard. Generic Formulations sales rose 31% to ₹677 crore, while Generic API revenue increased 1% to ₹625 crore.
Laurus Labs said its first commercial-scale peptide manufacturing plant in Vizag had been operationalised. The company also announced investments in oligonucleotides and peptide-resin technologies to expand its CDMO capabilities.
For the first half of FY27, revenue rose 31% to ₹4,233 crore and EBITDA reached ₹1,406 crore, the Economic Times reported. Laurus Labs also declared an interim dividend of ₹1 per share.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.